Efficacy of radiotherapy for adult patients with Langerhans cell histiocytosis.
- Author:
Ming-hui DUAN
1
;
Xiao HAN
;
Jian LI
;
Bing HAN
;
Wei ZHANG
;
Tie-nan ZHU
;
Jun-ling ZHUANG
;
Dao-bin ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Disease Progression; Disease-Free Survival; Female; Histiocytosis, Langerhans-Cell; radiotherapy; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2013;34(6):482-484
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze efficacy of radiotherapy for adult patients with Langerhans cell histiocytosis (LCH).
METHODSClinical features and efficacy of radiotherapy for biopsy-proven adult patient with LCH from January 2000 to October 2012 in our hospital were retrospectively analyzed.
RESULTSSeventeen (11 male and 6 female) adult LCH patients with a mean age of 31 (18-56) years old were treated by irradiation, all patients presented as single-system disease. The mean duration from diagnosis to irradiation was 8.3 (0-108) months. Although 12 of 17 patients (70.6%) had short-term response to radiotherapy, all patients but one (94.1%) progressed during long-term follow-up, the mean progression-free survival (PFS) was 14 (0-131) months. Of the progressed patients, one relapsed in situ, the remaining 15 patients progressed outside the irradiated region. Thirteen patients (76.5%) eventually progressed to multisystem disease.
CONCLUSIONThough radiotherapy for LCH in adults produced a high short-term response up to 70.6%, most of patients eventually progressed in situ or outside the irradiation region during long-term follow-up.
